FcRn inhibitors are a new class of drugs approved for the treatment of generalized myasthenia gravis, which work by blocking the binding between the FcRn receptor and IgG antibodies[1][6]. The neonatal Fc receptor (FcRn) has an important role in prolonging the life of IgG in the blood, including harmful autoantibodies that damage the neuromuscular junction in myasthenia gravis[1][4]. By blocking the FcRn receptor, the breakdown and secretion of IgG antibodies is accelerated, which leads to a decrease in their levels in the blood[1][3]. Clinical studies have shown that efgartigimod resulted in improvement of symptoms in 75% of patients, with IgG reduction of up to 70% achieved approximately one week after the last infusion[1][3]. Clinical improvement was seen rapidly, but its effects persisted for up to 8 weeks even when IgG levels returned to near baseline[3]. These drugs have a favorable safety profile with no serious adverse effects and no increased risk of infections[3]. So far, efgartigimod and rozanolixizumab have been approved for the treatment of generalized myasthenia gravis[6].